Time for a level playing field: inequalities in regulatory/approval processes—the example of bevacizumab in epithelial ovarian cancer

J Clin Oncol. 2015 May 10;33(14):1539-42. doi: 10.1200/JCO.2014.58.3690. Epub 2015 Apr 6.

Authors

Paul J Hoskins¹, Michael Fung-Kee-Fung², Dianne Miller³, Walter Gotlieb⁴

Affiliations

¹ British Columbia Cancer Agency, Vancouver, British Columbia, Canada phoskins@bccancer.bc.ca.
² University of Ottawa, Ottawa, Ontario, Canada.
³ Columbia Cancer Agency, Vancouver, British Columbia, Canada.
⁴ McGill University, Montreal, Quebec, Canada.

PMID: 25847922
DOI: 10.1200/JCO.2014.58.3690

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / economics*
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / economics*
Antineoplastic Agents / therapeutic use
Bevacizumab
Breast Neoplasms / drug therapy
Breast Neoplasms / economics
Canada
Carcinoma, Ovarian Epithelial
Clinical Trials as Topic
Colorectal Neoplasms / drug therapy
Colorectal Neoplasms / economics
Cost-Benefit Analysis
Disease-Free Survival
Drug Approval*
Drug Costs*
European Union
Evidence-Based Medicine
Female
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / economics
Neoplasms, Glandular and Epithelial* / drug therapy
Neoplasms, Glandular and Epithelial* / economics
Ovarian Neoplasms* / drug therapy
Ovarian Neoplasms* / economics
Politics
Recurrence
Survival Analysis
Treatment Outcome
United Kingdom
United States
United States Food and Drug Administration
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Vascular Endothelial Growth Factor A
Bevacizumab